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Electrohydraulic High-Energy 
Shock-Wave Treatment for 
Chronic Plantar Fasciitis
BY JOHN A. OGDEN, MD, RICHARD G. ALVAREZ, MD, 
RICHARD L. LEVITT, MD, JEFFREY E. JOHNSON, MD, AND MARIE E. MARLOW, RN
Investigation performed at the Atlanta Medical Center and the Skeletal Educational Association, Atlanta, Georgia; Southern Orthopaedic 
Foot and Ankle Center, Chattanooga, Tennessee; HealthSouth Doctor’s Hospital, Coral Gables, Florida; University of Rochester School of 
Medicine, Rochester, New York; Washington University School of Medicine, St. Louis, Missouri; Baylor University School of Medicine, 
Houston, Texas; American Sports Medicine Institute, Birmingham, Alabama; and University of Texas Medical Branch, Galveston, Texas
Background: Plantar fasciitis is a common foot disorder that may be resistant to nonoperative treatment. This study
evaluated the use of electrohydraulic high-energy shock waves in patients who failed to respond to a minimum of six
months of antecedent nonoperative treatment. 
Methods:  A randomized, placebo-controlled, multiply blinded, crossover study was conducted. Phase 1 consisted of
twenty patients who were nonrandomized to treatment with extracorporeal shock waves to assess the phase-2 study
protocol. In phase 2, 293 patients were randomized and an additional seventy-one patients were nonrandomized. Fol-
lowing ankle-block anesthesia, each patient received 100 graded shocks starting at 0.12 to 0.22 mJ/mm2, followed
by 1400 shocks at 0.22 mJ/mm2 with use of a high-energy electrohydraulic shock-wave device. Patients in the pla-
cebo group received minimal subcutaneous anesthetic injections and nontransmitted shock waves by the same pro-
tocol. Three months later, patients were given the opportunity to continue without further treatment or have an
additional treatment. This allowed a patient in the active treatment arm to receive a second treatment and a patient
who received the placebo to cross over to the active treatment arm. Patients were followed at least one year after the
final treatment. 
Results: Treatment was successful in seventeen of the twenty phase-1 patients at three months. This improved to
nineteen (95%) of twenty patients at one year and was maintained at five years. In phase 2, three months after treat-
ment, sixty-seven (47%) of the 144 actively treated patients had a completely successful result compared with forty-
two (30%) of the 141 placebo-treated patients (p = 0.008). At one year, sixty-five of the sixty-seven actively treated,
randomized patients maintained a successful result. Thirty-six (71%) of the remaining fifty-one nonrandomized pa-
tients had a successful result at three months. For all 289 patients who had one or more actual treatments, 222
(76.8%) had a good or excellent result. No patient was made worse by the procedure.
Conclusions: The application of electrohydraulic high-energy shock waves to the heel is a safe and effective noninva-
sive method to treat chronic plantar fasciitis, lasting up to and beyond one year.
Level of Evidence: Therapeutic study, Level I-1a (randomized controlled trial [significant difference]). See Instruc-
tions to Authors for a complete description of levels of evidence.
xtracorporeal shock waves have been applied since
1990, principally in Europe, for the treatment of nu-
merous musculoskeletal disorders1-4. One of the initial
treatment concepts was the noninvasive dissolution of a cal-
cific mass in the rotator cuff, similar to the break-up of a kid-
ney stone (lithotripsy)5-7. Several musculoskeletal entities that
have been treated include calcific tendinitis of the shoulder,
lateral epicondylitis, delayed union and nonunion of fractures,
chronic plantar fasciitis, Achilles and patellar tendinopathies,
and osteonecrosis of the femoral head1-9. Basic-science studies
increasingly are providing an understanding of the physio-
logic mechanisms of pain relief (often immediate) and the
modification and repair of the target tissue, which usually re-
quires weeks to months to occur10-29.
Extracorporeal shock-wave treatments have been ap-
plied to patients with chronic plantar fasciitis who have failed
to respond to multiple conservative pharmacologic and thera-
peutic interventions29-38. Recent randomized, controlled stud-
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ies have been published but with varying results because of
differences in study design, direction of the shock-wave delivery,
energy levels, size (volume) of the focused energy ellipsoid (f2)
that is transcutaneously transmitted to the fascia, and method
of forming the shock wave (electrohydraulic, electromagnetic,
and piezoelectric)32, 39-52. One study found that satisfactory re-
sults were maintained five years following electromagnetic
shock-wave treatment43. 
Randomized, placebo-controlled clinical trials for mus-
culoskeletal applications of high-energy shock waves have been
conducted in the United States43,46. One trial led to Food and
Drug Administration approval of the use of electrohydraulic
high-energy extracorporeal shock waves for the treatment of
plantar fasciitis in October 200044,53.
The present study assessed both the short and long-term
results of the application of high-energy electrohydraulic
shock waves in the treatment of plantar fasciitis. We hypothe-
sized that the likelihood of a successful result would be better
in patients receiving active treatment than in patients receiv-
ing a placebo. We further hypothesized that nonrandomized
patients would have an outcome equal to or greater than that
for the treated randomized patients. 
Methods
his study was conducted between 1996 and 2003. Phase-1
and phase-2 protocols were approved sequentially by the
Food and Drug Administration. Study approvals were for a
specific shock-wave generation device, the OssaTron (Health-
Tronics Surgical Services, Marietta, Georgia, and High Medi-
cal Technologies, Lengwil, Switzerland). This device generates
repetitive, high-energy shock waves by the electrohydraulic
method and transmits them transcutaneously through the
plantar skin into the target tissue. At all participating insti-
tutions, the study was conducted by members of the Depart-
ment of Orthopaedics and was approved by the institutional
review board.
Phase 1 involved the nonrandomized application of ex-
tracorporeal shock waves to patients with chronic plantar fas-
ciitis to assess any procedural or safety risks, to judge the
potential efficacy, and to assess the planned phase-2 study
protocol. All phase-1 study patients received active shock-
wave treatments. The phase-1 patients were allowed to receive
a second treatment at three months if they were dissatisfied
with the initial results, on the basis of the four outcome crite-
ria proposed for phase 2.
Phase 2 involved a prospective, randomized, placebo-
controlled, physician and patient-blinded, multicenter evalua-
tion to determine both the safety and the effectiveness of this
treatment method. Patients who received an actual treatment
were given the opportunity to have a second treatment if they
failed one or more of the four specific primary outcome pa-
rameters. Patients who received a placebo treatment similarly
could choose to receive one or two actual treatments (cross over).
All retreatment and crossover treatment decisions were made,
according to protocol, three months after the initial treatment.
Patients were not informed as to which study arm they were in
initially. An additional group of nonrandomized patients was
treated to allow training of the physician investigators. These
patients also were given the option of a second treatment at
three months if they failed any of the outcome parameters. All
of these nonrandomized patients in the training arm, who
were comparable with phase-1 patients, were aware that they
had an actual treatment.
A minimum of two physician investigators participated
at each study site. One investigator served as the treatment-
blinded evaluator, both for the baseline patient assessment
(according to specific inclusion and exclusion criteria detailed
in the Appendix) as well as for the follow-up evaluations. This
physician was not allowed to observe patient treatment. The
actual procedure was performed by a second trained physician
who was aware of the specific treatment rendered (with use of
a sealed randomization envelope), but who did not play any
role in evaluating the patient before or after treatment. 
Subjects were randomized with use of blocks stratified
by study site. Randomization was done by a statistician (Stat-
Tech Services) using numbered envelopes that were prepared
at a central facility and subsequently distributed to each treat-
ment facility. When a patient was to be treated, the study
coordinator was contacted and randomly assigned a specific
numbered envelope for the patient.
In both phases of the overall study, chronic heel-pain
syndrome was defined as moderate-to-severe heel pain in the
involved foot at the origin (enthesis) of the proximal plantar
fascia at the medial calcaneal tuberosity that had persisted for
at least six months. 
There were three important criteria for inclusion in the
study. (1) The patient had to have failed to respond after at
least three attempts of interventional conservative treatment,
which could include at least two prior courses of physical ther-
apy (Achilles tendon and plantar fascia-stretching exercises)
and the use of orthotic devices (heel cup, molded shoe insert,
night splint, or cast) and at least one prior course of pharma-
cologic treatment (aspirin, acetaminophen, nonsteroidal anti-
inflammatory drug, or corticosteroid injection). If the patient
had a corticosteroid injection, extracorporeal shock waves
were not administered unless at least four weeks had elapsed
since the injection. (2) The objective assessment of pain in the
proximal plantar fascia by an investigator, using a pain mea-
surement pressure device (dolorimeter), was ≥5 cm on a 10-
cm visual analog scale54,55. (3) The patient self-assessment of
pain after the first five minutes of walking in the morning was
≥5 cm on the 10-cm visual analog scale. 
All patients underwent monofilament sensory testing
(10-g retractable monofilament; Smith and Nephew, German-
town, Wisconsin) according to Semmes-Weinstein criteria to
screen for possible peripheral neuropathy56-58. Any patient who
tested positive at two or more of ten sites was excluded from
the study. Monofilament testing also was done at each post-
treatment evaluation. 
Patients with bilateral involvement were allowed to have
treatment of only one foot. However, these patients were dis-
couraged from participating during the enrollment evaluation
T
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because of the possible pharmacologic treatment of the con-
tralateral heel at or near the critical three-month evaluation
point that might adversely affect one of the four primary out-
come criteria. Any patient with pain in the contralateral heel
of >4 on the visual analog scale was excluded from the study.
Patients filled out a Short Form-36 (SF-36) question-
naire59 before treatment and at three months and twelve
months after treatment. All patients also were given specific
self-assessment questions regarding pain at rest, pain with ac-
tivity throughout the day, level of participation in recreational
activities, and the ability to work.
All patients had radiographs of the heel made in three
views during the pretreatment evaluation, at three months af-
ter treatment, and at the final follow-up evaluation at one
year. The presence or absence of a plantar heel spur was docu-
mented. The presence of intraosseous lesions, such as a calca-
neal cyst or subtalar arthritis, was exclusionary. 
The blinded investigator (evaluator) used a pressure
sensor (dolorimeter) to document objectively the amount of
pressure (lb/in2) that, when applied to the site of maximum
tenderness, elicited from the study subject a subjective base-
line visual analog scale response duplicating maximum daily
pain. At each subsequent posttreatment evaluation, the same
baseline dolorimeter pressure was applied and the patient was
asked to requantify the current amount of pain using the vi-
sual analog scale response. This method ensured consistency
of the objective pressure evaluation, while allowing for the
subjective evaluation, by the patient, of changes in the amount
of pain perceived at the time of follow-up. 
Patients were treated in an outpatient surgical center.
Prior to ankle-block anesthesia, the point of maximum plan-
tar surface tenderness was demarcated (targeted) with a surgi-
cal marking pen. The involved leg was draped from the direct
view of the patient. Ear protection devices were used by the
study subject and all involved personnel. Patients received ei-
ther a complete ankle-block anesthesia with lidocaine (the
treatment group) or three 1-mL subcutaneous injections of
lidocaine (the placebo group) prior to the application of shock
waves. The shock-wave treatments were applied with use of
the OssaTron device. Standard ultrasound gel was applied to
the heel for transcutaneous conduction of the shock waves
from the OssaTron into the heel tissues. The device was ad-
justed to maximize the focused treatment wave (f2) into the
plantar fascia60. Each study subject assigned to active treat-
ment received 100 graded shocks (14 to 18 kV; 0.12 to 0.22
mJ/mm2) to assess the effectiveness of anesthesia, followed by
1400 shocks at 18 kV (0.22 mJ/mm2) for a total of 1500 shocks,
all of which were applied at two per second (2 Hz). The total
energy delivered was 324.25 J. The treating physician continu-
ally manipulated the heel against the treatment head through-
out the shock-wave applications. Shock waves thus were
applied to the maximum pain site as well as an area in a 1-cm
radius surrounding it. 
For the patients assigned to placebo treatment, a styro-
foam block was placed against the treatment head to absorb
the shock waves by the presence of the multiple air cavities. In
addition, a fluid-filled intravenous bag was placed between the
styrofoam block and the subject’s heel to mimic the water-
filled treatment head. Patients who received a placebo treat-
ment did not have any coupling gel (ultrasound gel) applied to
the heel. Placebo patients also had 1500 shocks “delivered” ac-
cording to the aforementioned gradation protocol, effectively
duplicating the duration and noise of an active treatment. Pa-
tients who received the placebo treatment and patients who
received the active treatment were kept apart in the recovery
room to avoid any discussions and comparisons about what
occurred in the surgical suite.
All patients underwent evaluations within forty-eight
hours following treatment and at one, two, three, six, nine, and
twelve months. In both phase 1 and phase 2, an initial success
or failure status was assigned on the basis of the subjective and
objective findings three months after the initial treatment. This
three-month interval was selected on the basis of the expecta-
tion that some or all of the healing process most likely would
be evident at that time. Subsequently, patients either were fol-
lowed to one year without additional intervention or received
additional treatment followed by periodic evaluations until
one year following the additional treatment. Patients were en-
couraged to continue follow-up beyond one year. 
At three and twelve months, patients were assigned a
success or failure status according to each of four predeter-
mined primary criteria. (1) On the investigator assessment of
pain, the patient had to have a minimum improvement of
50% over the dolorimeter-induced baseline pain score, with a
required score of ≤4 on the visual analog scale. (2) On the pa-
tient self-assessment of pain on first walking in the morning,
success required a minimum improvement of 50% over the
pretreatment baseline and a visual analog scale score of ≤4. (3)
On the patient self-assessment of activity with regard to the
distance and time that he or she was able to walk without heel
pain, the patient had to demonstrate an improvement of ≥1
point on a 5-point scale or had to maintain a 0 or 1 baseline
level (no pain or minimal pain). (4) With regard to the use of
pain medications, prescription analgesics were not given after
treatment. Self-treatment with over-the-counter analgesics or
anti-inflammatory medications was documented with a medi-
cation log returned at each evaluation. Success required that
the patient had not taken any such medication (even for a rea-
son other than pain in the treated heel) between ten and
twelve weeks after treatment.
Each patient in the randomized group unequivocally
had to meet all four success criteria to attain an overall status
assignment of success. 
Patients who were assigned a failure status at three
months were informed that they could (1) withdraw from the
study to pursue alternative treatment modalities or (2) con-
tinue in the study by trying an additional active treatment as
allowed by the study protocol. All evaluations of retreatment
or crossover from placebo to active treatment were done ac-
cording to the same protocol as for the primary treatment-
placebo study arm.
The patients who elected to receive an additional treat-
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ment or treatments were classified arbitrarily as having a fail-
ure of the initial treatment. All patients receiving additional
treatment were followed according to the same protocol (with
evaluations at one, two, three, six, nine, and twelve months)
after the last applied shock-wave treatment. 
If patients did not complete the twelve-month follow-
up protocol, efforts were made to encourage compliance. Any
patient who failed to respond to these efforts was classified as
a failure in the outcome assessment.
Patient acceptance into the study, data collection, and
analysis were further blinded. At each center, a research assis-
tant collected questionnaire data (subject self-assessments and
SF-36) independently of the evaluating physician. Individual
centers were not allowed to communicate with each other.
Data from all centers were sent to an independent organiza-
tion, M2 and Associates, for composite compilation and initial
analyses. Final data sets and analyses were then sent to an out-
side statistician, Stat-Tech Services, to validate the results.
Univariate analyses were performed with use of the
Pearson chi-square statistic. Multiple logistic regression was
used to test jointly the explanatory variables that were signifi-
cant in the univariate analyses. The adjusted odds ratios were
presented with the respective 95% confidence intervals. Sig-
nificance was considered at a two-tailed level of <0.05. 
The study sample size was obtained on the basis of the
need to collect sufficient safety information. The original effi-
cacy sample size was calculated on the basis of an assumed re-
sponse of 70% in the active treatment arm and 30% in the
placebo arm, which was smaller than the sample size required
for adequate safety information. Additional subjects were added
after the study sample size was reached in order to allow contin-
ued patient access and obtain additional safety information.
The primary efficacy analysis was based on the success
status at three months. The p value for the inferential evalua-
tion of the null hypothesis of no treatment effect was obtained
with use of a likelihood ratio test controlling for study site.
The test statistic was obtained by evaluating the difference in
log-likelihood for the logistic model including the study site
and treatment and the logistic model including only the study
site. The Pearson chi-square test also was used to evaluate the
null hypothesis that there was no association between treat-
ment and response at three months.
To investigate the durability of the response through six
months and one year, the time-to-failure after the initial treat-
ment was compared with use of Kaplan-Meier methodology,
and inference was based on the log-rank statistic. Substantially
more follow-up data were available to support this analysis
than were available for the three-month analysis at the time of
the initial Food and Drug Administration submission. The
proportion of six-month and one-year responders was com-
pared, with use of a Pearson chi-square test, for all subjects
who had six months of follow-up data. A two-tailed Fisher ex-
act test was used to compare the distribution of successful out-
comes at three months for the patients who had retreatment
with electrohydraulic shock waves and the patients who ini-
tially had the placebo treatment. Secondary efficacy measures
of the visual analog scale scores for pain were summarized at
each visit through six months. The six-month and one-year
time-points included only subjects who were responders at
three months. The hypothesis of no treatment difference in
the mean percentage change from baseline was evaluated with
use of a t test assuming equal variance.
Selected demographic and baseline characteristics were
assessed for homogeneity in the subject population across
sites and treatment groups. The assessment of homogeneity
was used to assist in the interpretation of the efficacy and
safety analyses. For categorical variables, a logistic modeling
approach was used. For continuous variables, a general linear
modeling approach was used and inference was based on p
values associated with the type-III sums of squares.
Deviations from planned analyses included use of an
additional Pearson chi-square test to compare the proportion
of subjects with a successful outcome at six months. No fur-
ther confidence intervals were calculated, except for the 95%
confidence interval of the relative risk for success at three
months. Testing comparing the visual analog scale scores for
the patients who had retreatment with electrohydraulic shock
waves and the patients who were initially treated with placebo
was not performed.
Results
wenty patients were enrolled in the phase-1 study (Fig. 1).
The treating and evaluating physician was the same indi-
vidual, and all patients knew that they received active extra-
corporeal shock-wave treatment. Seventeen patients (85%)
had substantial improvement or complete relief of pretreat-
ment symptoms at three months. Three patients were not sat-
isfied with the results at three months and chose a second
treatment. Two of the three had symptomatic improvement,
whereas one continued to have no improvement. All twenty
patients were followed to one year, with a good-to-excellent
result maintained at one year in nineteen54. These nineteen pa-
tients reported continued relief of symptoms for sixty-five to
sixty-eight months later, and none had a recurrence of symp-
toms. The single patient who had no symptomatic improve-
ment continued to have chronic pain.
Phase 2 involved 344 patients, comprising 293 random-
ized and fifty-one nonrandomized study subjects (Figs. 2 and
3). This patient population was predominantly female (66.3%).
The mean age of the subjects at the time of enrollment was
48.6 years (range, nineteen to seventy-nine years; median
[and standard deviation], 49 ± 11.3 years). Age was not signif-
icantly associated with the three-month outcome (p = 0.138).
Gender, ethnicity, and pretreatment osteoarthritis in other
joints, such as the knee or the hip, were not significantly asso-
ciated with success or failure. 
Of the 148 randomized patients who had an active treat-
ment initially, 144 returned for all evaluations up to three
months and eighty-nine continued to twelve months. Of the
145 randomized patients who initially received a placebo, 141
returned for evaluations at three months and sixty-four con-
tinued to twelve months. Of the fifty-one nonrandomized pa-
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tients, forty-seven returned for evaluations at three months
and thirty-six continued to twelve months. Altogether 189
phase-2 patients (55%) cooperated in follow-up to at least one
year following the initial treatment.
Duration of Symptoms
All patient groups were similar with respect to the mean dura-
tion of symptoms prior to shock-wave or placebo treatment.
The duration of symptoms was significantly associated with
Fig. 1
Flowchart of phase-1 patients.
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success (p = 0.001). Adjusting for the duration of symptoms
affected the overall significance of the association between
treatment and success (p = 0.004). The analysis divided the
population into patients with a shorter duration of pain (less
than or equal to the median duration) and those with a
greater duration of pain (more than the median duration). Pa-
tients with a shorter duration of symptoms had higher re-
sponse rates, and the absolute difference in the success rates
Fig. 2
Flowchart of randomized phase-2 patients.
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between the two patient groups was similar in magnitude. The
difference in treatment success rates was 13% (52% for the ac-
tive treatment group compared with 39% for the placebo group)
for the patients with a shorter duration of pain and 20% (40%
for the active treatment group compared with 20% for the
placebo group) for the patients with a longer duration.
Investigator Heel-Pain Assessment
All treatment groups had comparable baseline pain scores
(Table I). Evaluation of the investigator assessment of heel
pain at four, eight, and twelve weeks indicated significant
treatment effects as early as the four-week visit. The percent-
age change (improvement) in investigator assessment of heel
pain at four, eight, and twelve weeks was 41%, 49%, and
59%, respectively, for active treatment subjects compared
with 27%, 32%, and 43%, respectively, for placebo treatment
subjects. The p values for the comparisons of active treat-
ment versus placebo at these visits were 0.018, 0.001, and
0.002, respectively. This dolorimeter-based visual analog
scale measurement at three months was the most sensitive
measure comparing patients who had received active treat-
ment with those who had been randomized to treatment
with a placebo (p = 0.002). This sensitivity was maintained
at twelve months (p = 0.005).
Fig. 3
Flowchart of nonrandomized phase-2 patients.
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Subject Self-Assessment of Morning Heel Pain
Baseline values were comparable (Table II). For the patient
self-assessment of morning heel pain, the mean score at four,
eight, and twelve weeks improved 45%, 50%, and 58%, re-
spectively, for the subjects who had active treatment and 31%,
39%, and 47%, respectively, for the subjects who had placebo
treatment. The p values for the comparisons of active treat-
ment and placebo effects at these visits were 0.002, 0.021, and
0.014, respectively. At twelve months, this difference was
maintained (p = 0.015).
Subject Self-Assessment of Activity-Related Pain
Baseline values were comparable (Table III). For the patient
self-assessment of pain with activity, the mean score at four,
eight, and twelve weeks improved 40%, 53%, and 51%, re-
spectively, for patients who had active treatment and 29%,
32%, and 47%, respectively, for subjects who had placebo
treatment. The p values for the comparisons of active treat-
ment and placebo effects at these visits were 0.024, 0.077, and
0.059, respectively. By twelve months, however, no difference
in subjective self-assessment of activity-related pain persisted
between the two groups.
Use of Pain Medications
This parameter had the least sensitivity to differentiate be-
tween actively treated patients and those who received the pla-
cebo as success levels in both groups were nearly identical.
Furthermore, over 70% of the patients took medications for
pain in another body region than the treated heel.
Repeat Procedures
In phase 2, forty-seven (61%) of the seventy-seven patients
who had active treatment and were assigned to a failure status
at twelve weeks chose to have retreatment, whereas eighty-
four (85%) of ninety-nine placebo-treated patients with a fail-
ure status at twelve weeks chose to undergo an active extracor-
poreal shock-wave treatment and nineteen had a second active
treatment. In the nonrandomized cohort, eleven (23%) of
forty-seven patients chose a second treatment. A total of 370
active extracorporeal shock-wave treatments were performed
in randomized and nonrandomized subjects. The difference
between the randomized, actively treated patients and the
placebo-treated patients with respect to the selection of a sec-
ond treatment was significant (p = 0.003). 
At three months, twenty-two of forty-two patients who
were initially actively treated and received a second active
treatment attained success. This success was maintained in
eighteen of the twenty-two patients at one year. Three months
after seventy-eight placebo-treated patients had crossover
treatment, thirty-six attained success. At one year, thirty-nine
patients were lost to follow-up. Of the remaining thirty-six pa-
tients, thirty had a successful outcome. Three months after a
repeat procedure, six of eleven nonrandomized subjects had a
successful outcome and six of eight had a successful outcome
at one year.
Complications
There were no complications in the phase-1 patients. The
most frequent phase-2-related complications in all groups were
pain after treatment and mild neurologic symptoms (numb-
ness or dysesthesia) principally related to the ankle-block
anesthesia. All patients had complete resolution of the post-
treatment neurologic symptoms by the three-month evalua-
tion, and no patient had neurologic complaints at one year. 
Rates of Treatment Success for Randomized Patients
Of the 144 phase-2 patients who were randomized to active
treatment, 47% met all four success criteria at three months




Baseline (n = 364) 7.83 8.08 8.14 6.85
12 weeks (n = 352) 3.17 3.43 4.28 2.36
1 year (n = 209) 1.34 1.41 3.54 1.27
*The values are given as the mean score on the visual analog scale.
TABLE I Physician Assessment of Heel Pain* 
Phase 1
Phase 2
Treated Placebo (No Cross Over) Placebo (Cross Over) Nonrandomized
Baseline (n = 364) 7.95 7.80 7.99 7.67 7.83
12 weeks (n = 352) 2.95 3.23 4.52 2.50 2.01
1 year (n = 209) 1.67 1.87 5.13 1.73 1.39
*The values are given as the mean score on the visual analog scale.
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compared with 30% of the 141 subjects who received placebo
treatment (p = 0.008). Of the fifty-one nonrandomized pa-
tients, 67% met all four success criteria. Of the eighty-four pa-
tients who had been randomized to placebo treatment, failed
to meet the four success criteria, and subsequently elected to
have an active treatment, 43% subsequently achieved a success
at three months. The time to treatment failure was evaluated
starting at three months and followed through to twelve
months. A significant difference was found when patients who
had one or more treatments (including crossover treatments)
with success were compared with patients (actively treated
and placebo-treated) who were rated as having a failure (log-
rank test, chi-square = 9.68; p = 0.0019).
The primary efficacy comparison for success of all four
components of efficacy at three months indicated a robust
treatment effect (p = 0.003). Accordingly, the relative risk for
success at three months (active treatment relative to placebo)
was 1.56 (95% confidence interval, 1.15 to 2.13), implying a
>50% increase in the chance of success at three months with
active treatment compared with placebo.
In the phase-2 patients, the rate of success maintained at
twelve months was 93% for those initially treated actively, 83%
for those who crossed over from initial placebo treatment, and
93% for those who were not randomized. In contrast, only
twenty-five (18%) of the 141 patients who received the placebo
and chose no subsequent treatment at three months had a suc-
cess at twelve months. At twelve months, the differences be-
tween the actively treated patients and the placebo-treated
patients showed a continuing significance (p = 0.002). Thirty-
four patients subsequently were followed between twelve and
twenty-seven months, and all maintained the successful re-
sults. The overall maintenance of a successful outcome was
found to be significant (Fisher exact test, p = 0.040).
Analysis of All Treated Patients
Although only the randomized patients were used for the ini-
tial three-month and final one-year statistical analyses sub-
mitted to the Food and Drug Administration, the results in all
patients were subsequently assessed in a clinically relevant
manner with use of a grading system similar to one commonly
used in most published European musculoskeletal shock-wave
outcome studies61. Patients who had initial visual analog scale
scores (in the first three outcome assessment categories) of >8
frequently met the criterion of 50% improvement, but they
failed to have a visual analog scale score of ≤4. All 289 phase-1
and 2 patients who received one or two actual shock-wave
treatments were grouped together and were rated as having an
excellent result if all four success criteria were met, a good re-
sult if two or three of the four success criteria were met, a fair
result if one of the four success criteria were met, or a poor re-
sult if none of the four success criteria were met.
With use of this grading system, 147 (50.9%) of 289 pa-
tients had an excellent result and seventy-five (26%) had a good
result (Table IV), for a combined total of 222 patients (76.8%)
in whom the result was considered a success, even when pain
relief was not complete in one of the outcome categories. 
Discussion
hronic heel pain that adversely affects employment or lif-
estyle is a common complaint. A heel spur is evident inC
TABLE IV Summary of Data on 289 Patients Treated During the Food and Drug Administration Clinical Trial
Outcome*
Excellent Good Fair Poor
Phase 1 19 — 1 —
Phase-2 treated 67 37 21 19
Phase-2 crossover treated 36 24 8 10
Phase-2 nonrandomized 25 14 5 3
Total† 147 75 35 32
*The outcome was evaluated according to the criteria described by Roles and Maudsley61, with an excellent outcome indicating that all four
criteria for success were met; good, that two or three of the four criteria were met; fair, that one of the four criteria was met; and poor, that
none of the four criteria was met. †A total of 222 patients had a good or excellent result, and sixty-seven patients had a fair or poor result.




Baseline (n = 364) 3.18 3.49 3.53 2.63
12 weeks (n = 352) 0.91 1.72 1.88 0.85
1 year (n = 209) 0.61 0.83 1.56 0.63
*The values are given as the mean score on the visual analog scale.
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50% to 60% of patients having a diagnosis of heel pain. In one
study, electrohydraulic shock waves delivered at the energy
level used for plantar fasciitis (18 to 20 kV; 0.22 to 0.27 mJ/
mm2) caused no change in the heel spur when one was present
nor did the presence or absence of an inferior heel spur affect
the likelihood of a positive response62.
The initial treatment of proximal plantar fasciitis should
be conservative (nonsurgical), an approach that may be suc-
cessful in as many as 90% of patients by providing substantial,
if not complete, relief of the symptoms63. However, there is no
consensus for a specific treatment protocol, particularly when
symptoms last for more than three months.
Evaluations of the nonoperative methods for treating
chronic plantar fasciitis have been difficult to assess statisti-
cally, since many protocols have included multiple and vari-
able nonoperative regimens within the same study, and few
nonoperative treatments have been analyzed with randomized
controlled studies63. Martin et al. reviewed numerous studies
on nonoperative treatment and showed a wide variation in
acceptable outcomes, ranging from 44% to 82% (average, 60.3%)
of patients who had complete relief of heel pain64. Interest-
ingly, in that study, only 51% of the patients were completely
asymptomatic following treatment, whereas 82% were satis-
fied with the final outcome relative to the amount of residual
pain64. We found similar outcome perceptions and satisfac-
tion levels by the patients who received shock-wave treatment;
complete pain relief was not needed for patient satisfaction
with the eventual outcome. 
Of interest was the lower than expected rate of retreat-
ment in the active treatment arm of study. The study was de-
signed on the assumption that the majority of subjects who
failed to respond to the primary treatment would elect to have
a second treatment. However, forty-seven (61%) of the sev-
enty-seven treated subjects who failed to meet all four success
criteria chose retreatment compared with eighty-four (85%)
of the ninety-nine patients who failed the placebo treatment.
This observation suggests that many subjects who were assigned
a final “fail” status (less than four of the four criteria for success
were met) may have been sufficiently satisfied with the out-
come that they did not want a second treatment. 
When such noninvasive methods fail to achieve relief
in a reasonable period of time, surgery frequently is recom-
mended. A recent study found that patients undergoing elec-
trohydraulic high-energy shock-wave application and patients
undergoing percutaneous partial fasciotomy had comparable
outcomes65. However, the former group (patients who had ex-
tracorporeal shock waves) had a more rapid return to the ac-
tivities of work and daily living.
The technology of applying shock waves to the heel is
similar to that used for lithotripsy. Several devices have been
designed specifically for the treatment of musculoskeletal con-
ditions. This is necessary since the energy levels, the focused
volume of the energy ellipsoid (f2), the central size of the
maximum energy level within the ellipsoid, and the depth of
penetration used in lithotripsy are different from those con-
sidered safe and effective for musculoskeletal tissues that are
not as deeply situated as the kidneys and ureters. These mus-
culoskeletal devices generate and focus the shock waves by one
of three basic methods—electrohydraulic, electromagnetic, or
piezoelectric60. The differences in shock-wave energy to the
target tissue relate specifically to the method of generation of
the shock wave, the size and volume of the f2 ellipsoid, and the
depth of energy penetration. These factors may result in sig-
nificant differences in the potential clinical efficacy2,60. Com-
parison studies with lithotriptors (for renal stones only) have
described the electrohydraulic method as being more clini-
cally effective in stone fragmentation compared with electro-
magnetic or piezoelectric devices66. The machine used for the
current musculoskeletal studies employed electrohydraulic
shock-wave generation and was the first shock-wave device
approved by the Food and Drug Administration for any
musculoskeletal indications53. Since direct comparison stud-
ies of machines have not been done, there is no information
concerning the relative efficacy of one method of shock-wave
generation over any other for specific musculoskeletal tissue
applications60.
Electrohydraulic application is based on one treatment
in most patients, whereas electromagnetic and piezoelectric
devices, as described in most European-based publications,
routinely use multiple (three to six) treatments1,2. Buchbinder
et al. assessed a low-energy electromagnetic device in a ran-
domized, double-blind, placebo-controlled study with use of
three treatments49. They found no differences between the pa-
tients who received active treatment and those who received
the placebo. This observation suggested that the overall effi-
cacy of low-energy, multiple shock-wave treatments for mus-
culoskeletal applications was questionable. However, such a
generalization was inappropriate because of limitations of that
particular study (the patients were treated as early as six weeks
after symptom onset, actual shock waves were delivered to
placebo-treated patients, and variable numbers of shocks [mJ/
mm2 and total energy (Joules)] per patient were used) com-
pared with other studies.  Furthermore, patients received no
specific physical examinations before and after treatment, and
no orthopaedist was involved in the study. A “trained techni-
cian” delivered the treatment after a radiologist focused the
device with use of ultrasound. In the current study, patients
had to have had symptoms for a minimum of six months, all
patients received exactly the same energy levels, shock waves
were not delivered to placebo patients, and trained orthopae-
dists actively participated in the evaluation and treatment of
the patients. When the Food and Drug Administration ap-
proved the OssaTron device, one stipulation was that treat-
ment should be administered only by an appropriately trained
and certified physician or podiatrist.
Other studies on low-energy electromagnetic shock
waves in which patients received the same dosage and those
treated with a placebo received no shock waves, with delivery in
a transverse direction, also showed no effective difference be-
tween the actively treated patients and the patients who re-
ceived the placebo50,51. Those studies (compared with the
present study on high-energy electrohydraulic shock waves) sug-
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gested that there are different tissue responses to shock waves
contingent upon the method of generation (electrohydraulic or
electromagnetic), the level of energy applied, or the direction of
delivery (perpendicular to the plantar surface or transverse).
Low-energy electromagnetic and piezoelectric devices
have an adjunct ultrasound device that must be used to focus
f2 because the low-energy shock waves are delivered in a me-
dial-to-lateral direction, rather than perpendicular to the
plantar surface. This technique delivers shock waves to the
thinnest portion of the fascia, which is done to minimize
shock-wave impaction against the calcaneus, thus avoiding
pain stimulation and the need for anesthesia. This technique
requires additional expertise in ultrasound imaging by the
treating physician. With transverse delivery, the foot is held in
a fixed position. Accordingly, only a small section of the fascia
is impacted by the shock waves. In contrast, the electrohy-
draulic shock waves are administered through the plantar sur-
face (a wider surface area), targeting the point of maximal
pain, and the foot is continually manipulated to treat an area 2
cm in diameter around the predetermined focal point of max-
imal pain. Some of the shock waves strike the calcaneus and
bone and are reflected back into the involved fascia, poten-
tially increasing the total effect of each shock wave.
One study stated that the low-energy treatment was
considered “unpleasant by all patients.”32 Treatment with high-
energy shock waves, particularly those generated electrohy-
draulically, requires some type of anesthetic agent. In our
study, patients receiving the actual high-energy shock waves
were administered an ankle block. Since the approval of the
device by the Food and Drug Administration, we have also
used conscious sedation. This anesthetic technique also al-
lows the treatment of both heels when appropriate levels of
chronic fascial pain are present bilaterally67.
Rompe et al. performed several studies on the treatment
of plantar fasciitis with shock waves4,32,39,43. Those studies all
used electromagnetically generated shock waves, involved
multiple treatments, and varied considerably with respect to
the treatment protocols. All outcome evaluations emphasized
subjective improvement, rather than complete relief of heel
pain, and used outcome criteria that were much less restrictive
than those used in our study. In one study, Rompe et al. re-
cently reported on patients who had a successful outcome five
years after treatment with low-energy extracorporeal shock
waves43. Hammer et al. reported on forty-four patients with
chronic plantar fasciitis who were treated with piezoelectric
shock-wave generation42. There were no control patients. In
twenty-four of forty-four patients (55%), the visual analog
scale improved; however, only thirteen patients (30%) rated
the outcome as completely successful. 
The mechanism of shock-wave action in soft tissues
(tendon and fascia) is still under investigation. Rompe et al.
showed no tendon cellular damage in a rabbit model with use
of energy levels normally applied clinically for the treatment
of plantar fasciitis10,11. They demonstrated neovascular prolif-
eration as did Wang et al.14,22. When shock waves are applied to
bone (at a much greater energy level and number of shocks),
microfractures and osteocyte damage occur, followed by a
proliferation of osteoblasts and elaboration of bone1,2,4,17,20,23-26.
A similar microdisruption of the thickened plantar fascial ori-
gin probably occurs, resulting in an inflammatory and soft-
tissue reparative response2,10,14.
This study presents robust evidence of a treatment effect.
The primary efficacy end point of success at three months and
the analysis of sustained response were both highly significant
(p < 0.01). Analyses of the long-term (one-year) response sup-
ported a continuing treatment difference. Hence, there is am-
ple evidence that electrohydraulically generated high-energy
transcutaneous shock-wave treatment is an effective treatment
of heel pain due to chronic plantar fasciitis when compared
with placebo. We believe that our data support the use of elec-
trohydraulic high-energy shock-wave treatment before consid-
eration of any open or endoscopic surgical treatment. 
Appendix
A table showing the complete inclusion-exclusion crite-
ria is available with the electronic versions of this article,
on our web site at jbjs.org (go to the article citation and click
on “Supplementary Material”) and on our quarterly CD-
ROM (call our subscription department, at 781-449-9780, to
order the CD-ROM).  
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